REGN22530 for Glaucoma
(BAHAMA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP).
REGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure.
The study is looking at:
* What side effects REGN22530 might cause
* How much REGN22530 is in the blood and eye fluid at different times
* If the body has any reactions to REGN22530 (which may cause REGN22530 to not work as well)
* How the body and eye pressure respond after having REGN22530, which can help researchers understand why REGN22530 works better in some people than others
* How well REGN22530 works
Who Is on the Research Team?
Clinical Trial Management
Principal Investigator
Regeneron Pharmaceuticals
Are You a Good Fit for This Trial?
This trial is for adults with mild to moderate primary open angle glaucoma or ocular hypertension. Participants need to have reasonably good vision in both eyes and clear enough eyes for imaging tests. People who recently had certain eye surgeries or have other serious eye problems may not be eligible.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- REGN22530
Trial Overview
The study is testing REGN22530, an experimental drug designed to lower pressure inside the eye by helping fluid drain out better. Researchers will monitor how well it works, its side effects, and how the body responds over time.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Regeneron Pharmaceuticals
Lead Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.